Transforming growth factor-beta (TGF-beta) is a family of multifunctional 25 kDa proteins. TGF-beta was originally identified because of its ability to induce the growth of normal rodent fibroblasts in soft agar, but is now known as a potent growth inhibitor for many different cell types. In addition, TGF-beta is known to regulate the differentiation of cells, induce chemotaxis of cells, and to induce the accumulation of extracellular matrix proteins. In vivo, TGF-beta stimulates the repair of soft as well as hard tissues. It also acts as a potent immunosuppressant. TGF-beta is produced as latent high molecular weight complexes; since it is produced by many different cell types, and most cells have receptors for TGF-beta, the activation of latent TGF-beta is likely to be an important step in the regulation of its action. TGF-beta exerts its effects by binding to specific cell surface receptors. The type I and type II TGF-beta receptors are suggested to be the most important for signal transduction; a recent report has disclosed that the type II receptor has a serine/threonine kinase domain. Since TGF-beta is a potent growth regulator with multifunctional activity, it may be useful in the treatment of certain clinical disorders. Local application of TGF-beta is shown to accelerate wound healing. Since an increase in TGF-beta activity is often observed in various fibrotic disorders, antagonists for TGF-beta might be valuable in the treatment of such diseases.
No takes yet. Share an insight, caveat, or question.
Miyazono et al. (1992) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: